JPWO2020209285A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020209285A5 JPWO2020209285A5 JP2021513667A JP2021513667A JPWO2020209285A5 JP WO2020209285 A5 JPWO2020209285 A5 JP WO2020209285A5 JP 2021513667 A JP2021513667 A JP 2021513667A JP 2021513667 A JP2021513667 A JP 2021513667A JP WO2020209285 A5 JPWO2020209285 A5 JP WO2020209285A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- pharmaceutical composition
- acid strand
- composition according
- analogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025081949A JP2025118886A (ja) | 2019-04-08 | 2025-05-15 | 筋疾患治療用医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019073832 | 2019-04-08 | ||
| JP2019073832 | 2019-04-08 | ||
| PCT/JP2020/015818 WO2020209285A1 (ja) | 2019-04-08 | 2020-04-08 | 筋疾患治療用医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025081949A Division JP2025118886A (ja) | 2019-04-08 | 2025-05-15 | 筋疾患治療用医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020209285A1 JPWO2020209285A1 (https=) | 2020-10-15 |
| JPWO2020209285A5 true JPWO2020209285A5 (https=) | 2023-04-17 |
| JP7687682B2 JP7687682B2 (ja) | 2025-06-03 |
Family
ID=72750688
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513667A Active JP7687682B2 (ja) | 2019-04-08 | 2020-04-08 | 筋疾患治療用医薬組成物 |
| JP2025081949A Pending JP2025118886A (ja) | 2019-04-08 | 2025-05-15 | 筋疾患治療用医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025081949A Pending JP2025118886A (ja) | 2019-04-08 | 2025-05-15 | 筋疾患治療用医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220175817A1 (https=) |
| EP (1) | EP3954395A4 (https=) |
| JP (2) | JP7687682B2 (https=) |
| CN (1) | CN113677374A (https=) |
| WO (1) | WO2020209285A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| CN117120456A (zh) * | 2020-12-11 | 2023-11-24 | 卫材R&D管理有限公司 | 聚-吗啉代寡核苷酸缺口体 |
| US20240240183A1 (en) * | 2021-05-25 | 2024-07-18 | National University Corporation Tokyo Medical And Dental University | Heteronucleic acid containing scpBNA or AmNA |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US20250339459A1 (en) * | 2021-08-19 | 2025-11-06 | National University Corporation Tokyo Medical And Dental University | Modified heteronucleic acid containing morpholino nucleic acid |
| US20240390508A1 (en) | 2021-08-21 | 2024-11-28 | Takeda Pharmaceutical Company Limited | Human transferrin receptor binding peptide-drug conjugate |
| US20240366775A1 (en) | 2021-08-24 | 2024-11-07 | Peptidream Inc. | Human transferrin receptor binding antibody-peptide conjugate |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| GB202215614D0 (en) * | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| AR131145A1 (es) | 2022-11-24 | 2025-02-19 | Proqr Therapeutics Ii Bv | Oligonucleótidos antisentido para el tratamiento de hemocromatosis hfe hereditaria |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| CA3276262A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| JP2024089860A (ja) * | 2022-12-22 | 2024-07-04 | 学校法人東京薬科大学 | Ｚｉｃ５発現を調節するための核酸複合体 |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| EP4669753A1 (en) | 2023-02-20 | 2025-12-31 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| WO2024206175A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| AU2024246572A1 (en) | 2023-03-27 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2024256620A1 (en) | 2023-06-16 | 2024-12-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurodegenerative disease |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| GB202405143D0 (en) | 2024-04-11 | 2024-05-29 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of poly-q disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2026080897A1 (en) | 2024-10-11 | 2026-04-16 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of chronic pain |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060014289A1 (en) * | 2004-04-20 | 2006-01-19 | Nastech Pharmaceutical Company Inc. | Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
| EP2023940B1 (en) | 2006-05-05 | 2011-06-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of sglt2 |
| ES2603379T3 (es) | 2006-10-09 | 2017-02-27 | Roche Innovation Center Copenhagen A/S | Compuestos antagonistas de ARN para la modulación de PCSK9 |
| WO2008049085A1 (en) | 2006-10-18 | 2008-04-24 | Isis Pharmaceuticals, Inc. | Antisense compounds |
| CN112574988A (zh) * | 2008-10-24 | 2021-03-30 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
| CA2759899A1 (en) * | 2009-04-24 | 2010-10-28 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
| AU2012353330B2 (en) | 2011-12-16 | 2018-04-19 | National University Corporation Tokyo Medical And Dental University | Chimeric double-stranded nucleic acid |
| CA2901983A1 (en) * | 2013-03-01 | 2014-09-04 | National University Corporation Tokyo Medical And Dental University | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent |
| RS58529B1 (sr) * | 2013-03-14 | 2019-04-30 | Sarepta Therapeutics Inc | Sastavi koji preskaču egzon za tretiranje mišićne distrofije |
| ES2700277T3 (es) * | 2013-05-30 | 2019-02-14 | Univ Nat Corp Tokyo Medical & Dental | Agentes de doble cadena para el suministro de oligonucleótidos terapéuticos |
| CN105324119A (zh) * | 2013-06-16 | 2016-02-10 | 国立大学法人东京医科齿科大学 | 具有外显子跳跃效应的双链反义核酸 |
| EP4674963A3 (en) * | 2013-12-09 | 2026-04-29 | Baylor College of Medicine | Hippo and dystrophin complex signaling in cardiomyocyte renewal |
| EP3353306A4 (en) * | 2015-09-25 | 2019-06-05 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EP3858993A1 (en) * | 2015-10-09 | 2021-08-04 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| EP3366773A4 (en) * | 2015-10-23 | 2019-06-12 | Rena Therapeutics Inc. | NUCLEIC COMPLEX |
| EP3517610A4 (en) * | 2016-09-23 | 2020-05-27 | National University Corporation Tokyo Medical and Dental University | THROUGH HETERODUPLEX NUCLEIC ACID THROUGH BLOOD BRAIN CABINET |
| US11260134B2 (en) * | 2016-09-29 | 2022-03-01 | National University Corporation Tokyo Medical And Dental University | Double-stranded nucleic acid complex having overhang |
| US11274300B2 (en) * | 2017-01-19 | 2022-03-15 | Proqr Therapeutics Ii B.V. | Oligonucleotide complexes for use in RNA editing |
| GB201711809D0 (en) * | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| EA201991450A1 (ru) * | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| JP2020536058A (ja) * | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| JP2019073832A (ja) | 2017-10-18 | 2019-05-16 | 合同会社型壱 | 帽子の製造方法、及びこれに用いる型 |
-
2020
- 2020-04-08 EP EP20788494.1A patent/EP3954395A4/en active Pending
- 2020-04-08 WO PCT/JP2020/015818 patent/WO2020209285A1/ja not_active Ceased
- 2020-04-08 JP JP2021513667A patent/JP7687682B2/ja active Active
- 2020-04-08 US US17/602,035 patent/US20220175817A1/en active Pending
- 2020-04-08 CN CN202080025994.6A patent/CN113677374A/zh active Pending
-
2025
- 2025-05-15 JP JP2025081949A patent/JP2025118886A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020209285A5 (https=) | ||
| JP2023123491A5 (https=) | ||
| CN114681621B (zh) | 肽寡核苷酸缀合物 | |
| JP5209204B2 (ja) | ポリマーオリゴヌクレオチドプロドラッグ | |
| JPWO2023026994A5 (https=) | ||
| JP2010533171A5 (https=) | ||
| JP7269968B2 (ja) | ペプチド担体上の多重オリゴヌクレオチド部分 | |
| US20200385735A1 (en) | Modified gapmer oligonucleotides and methods of use | |
| JP2018530560A5 (https=) | ||
| JP2021500016A5 (https=) | ||
| JP2021532784A (ja) | アンチセンス送達のための三量体ペプチド | |
| JPWO2023022229A5 (https=) | ||
| CN114615998A (zh) | 缀合物及其用途 | |
| US20040072743A1 (en) | Pharmaceutical composition of modified pna molecules | |
| WO2015172889A1 (de) | Peptid-nukleinsäuren-monomere und -oligomere | |
| JP2013537404A5 (https=) | ||
| JPWO2021187392A5 (https=) | ||
| AU2021226089A1 (en) | Antisense nucleic acid inducing skipping of exon 51 | |
| IL317141A (en) | Oleic acid-conjugated oligonucleotides and uses thereof | |
| JP2001524942A (ja) | アンチセンス・オリゴヌクレオチド薬物 | |
| Tamamura et al. | Synthesis and evaluation of bifunctional anti-HIV agents based on specific CXCR4 antagonists-AZT conjugation | |
| JP2004538272A5 (https=) | ||
| JPWO2022192749A5 (https=) | ||
| JP5865347B2 (ja) | ポリアミド化合物及びミトコンドリア遺伝子疾患治療用医薬組成物 | |
| WO2017043639A1 (ja) | キメラデコイ |